BACKGROUND: The success of hematopoietic stem cell transplantation (HSCT) depends critically on human leukocyte antigen (HLA) matching between donor and recipient. While traditional matching focuses o...

INTRODUCTION: Cytomegalovirus (CMV) reactivation is a major cause of mortality following haploidentical hematopoietic stem cell transplantation (haplo-HSCT). The application of conventional therapies ...

Multiantigen targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen targeting therapy. Our initial experience with a biva...

A collaborative podcast featuring the latest systematic reviews and trials

The standard 100 mg/kg dose of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis after matched allogeneic stem cell transplantation (ASCT) is associated with imp...

BACKGROUND: A myeloablative busulfan (Bu) and fludarabine (Flu) regimen that includes fractionating Bu and extending its delivery time results in low toxicity, permitting its use in stem cell transpla...

BACKGROUND: Umbilical cord blood (UCB) can be collected in utero (before placental delivery) or ex utero (after placental delivery). While in utero collection is standard, ex utero collection is less ...

Donor selection in allogeneic haematopoietic stem cell transplantation (allo-HSCT) requires balancing donor safety and recipient survival. We aimed to identify dual-association donor factors (DADFs)-d...

Background and progress update on the JLA PSP Blood Transfusion and Donation survey